Clinical safety of biosimilar recombinant human erythropoietins

Bibliography

• Lin FK, Suggs S, Lin CH, Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci 1985;22:7580-4
   Google Scholar
• Eschbach JW, Egrie JC, Downing MR, Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8
   PubMed Web of Science ®Google Scholar
• Barosi G, Bosi A, Abbracchio MP, Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011;96:937-42
   PubMed Web of Science ®Google Scholar
• Lonneman G, Macdougall IC. Biosimilar epoetins in renal anemia. Current status and insights from European practice. Eur Nephrol 2011;5:101-7
   Google Scholar
• Schellekens H. How similar do ‘biosimilars' need to be? Nature Biotech 2004;22:1357-9
   Google Scholar
• Singh AK. Biosimilars: what are the issues? Available from: http://www.patientsorganizations.org/showarticle.pl?id=766. [Last accessed 23 July 2012]
   Google Scholar
• Schellekens H. Biosimilar proteins: how similar are they? Eur J Hosp Pharm 2004;3:43-7
   Google Scholar
• Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:954-62
   PubMed Web of Science ®Google Scholar
• Deechongkit S, Aoki KH, Park SS, Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci 2006;95:1931-43
   Google Scholar
• Brinks V, Hawe A, Basmeleh AHH, Quality of original and biosimilar epoetin products. Pharm Res 2011;28:386-93
   PubMed Web of Science ®Google Scholar
• For HX575. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000725/human_med_000675.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 Last accessed 23 July 2012]
   Google Scholar
• For SB309. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000872/human_med_001031.jsp&mid=WC0b01ac058001d124 [Last accessed 23 July 2012]
   Google Scholar
• For XM01. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001033/human_med_001204.jsp&mid=WC0b01ac058001d124 [Last accessed 23 July 2012]
   Google Scholar
• Schellekens H. Biosimilar therapeutics – what do we need to consider? NDT Plus 2009;2(suppl 1):i27-36
   PubMedGoogle Scholar
• Ryff JC, Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci 2003;23:254-6
   Web of Science ®Google Scholar
• Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001;90:1-11
   PubMed Web of Science ®Google Scholar
• Gershon SK, Luksenburg H, Coté TR, Pure red cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1584-5
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR, Pure red cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18:473-80
   PubMed Web of Science ®Google Scholar
• Aapro M. An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. Oncologist 2009;14(suppl 1):1-5
   PubMedGoogle Scholar
• Bennett CL, Silver SM, Djulbegovic B, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar
• Aapro MS, Birgegård G, Bokemeyer C, Erythropoietins should be used according to guidelines. Lancet Oncol 2008;9:412-13
   PubMed Web of Science ®Google Scholar
• Sörgel F, Thyroff-Friesinger U, Vetter A, Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomized controlled trial. BMC Clin Pharmacol 2009;9:10
   PubMedGoogle Scholar
• Sörgel F, Thyroff-Friesinger U, Vetter A, Biosimilarity of HX575 (recombinant human epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol Ther 2009;47:391-401
   PubMed Web of Science ®Google Scholar
• Haag-Weber M, Vetter A, Thyroff-Friesinger U. INJ-Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009;72:380-90
   PubMed Web of Science ®Google Scholar
• Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anemia in patients with solid tumours. Onkologie 2009;32:168-74
   PubMed Web of Science ®Google Scholar
• Sörgel F, Thyroff-Friesinger U, Vetter A, Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 2009;83:122-30
   PubMed Web of Science ®Google Scholar
• Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamics profiles of one US-marketed and two European-marketed epoetin alfas. A randomized prospective study. Drugs R D 2011;11:61-75
   PubMedGoogle Scholar
• Haag-Weber M, Eckardt KU, Hörl WH, Safety, immunogenicity, and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multicentre, randomized, double-blind study. Clin Nephrol 2012;77:8-17
   PubMed Web of Science ®Google Scholar
• Kerkhofs L, Boschetti G, Lugini A, Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy induced anemia: real-life clinical experience. Fut Oncol 2012; Published online 23 March 2012
   PubMed Web of Science ®Google Scholar
• Gesualdo L, London G, Turner M, A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anemia in hemodialysis patients: background and methodology of the MONITOR-CKD5 study. Intern Emerg Med 2011; Published online 18 May 2011
   Web of Science ®Google Scholar
• Hörl WH, Locatelli F, Haag-Weber M, Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10 – 12 g/dL. Clin Nephrol 2012;78:24-32
   PubMed Web of Science ®Google Scholar
• Seidl A, X M, Fischer R, Tungsten-mediated unfolding and aggregation of epoetin alfa in prefilled syringes as root cause for the occurrence of neutralising antibodies in an investigational clinical trial of subcutaneous administration. Pharm Res 2011; Published online 18 November 2011
   Google Scholar
• Kirkov V, Dimitrova V, Siebert-Weigel M, Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd communication: a monocentric, double-blind, randomized, single dose, three-period cross-over trial in healthy volunteers. Arzneimittelforschung 2008;58:220-4
   PubMed Web of Science ®Google Scholar
• Wizemann V, Rutkowski B, Baldamus C, Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of anemia. Curr Med Res Opin 2008;24:625-37
   PubMed Web of Science ®Google Scholar
• Krivoshiev S, Todorov VV, Manitius J, Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anemia. Curr Med Res Opin 2008;24:1407-15
   PubMed Web of Science ®Google Scholar
• Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 2008;25:1215-28
   PubMed Web of Science ®Google Scholar
• Tzekova V, Mihaylov G, Elezovic I, Koytchev R. Epoetin Zeta Oncology Study Group. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anemia. Curr Med Res Opin 2009;25:1689-97
   PubMed Web of Science ®Google Scholar
• Kirkov V, Dimitrova V, Siebert-Weigel M, Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st communication: a monocentric, open, randomized, single dose, two-period cross-over trial in healthy volunteers. Arzneimittelforschung 2008;58:215-19
   PubMed Web of Science ®Google Scholar
• Krivoshiev S, Wizemann V, Czekalski S, Therapeutic equivalence of epoetin zeta and epoetin alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010;27:105-17
   PubMed Web of Science ®Google Scholar
• Więcek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia patients on dialysis: posthoc analysis. Adv Ther 2010;27:941-52
   PubMed Web of Science ®Google Scholar
• Lonneman G, Wrenger E. Biosimilar epoetin zeta in nephrology – a single dialysis center experience. Clin Nephrol 2011;75:59-62
   PubMed Web of Science ®Google Scholar
• Gertz B, Kohler E, Kes P, Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin 2010;26:2393-402
   PubMed Web of Science ®Google Scholar
• Tjulandin SA, Bias P, Elsässer R, Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy: a randomised control trial. Arch Drug Inf 2010;3:45-53
   PubMedGoogle Scholar
• Tjulandin SA, Bias P, Elsässer R, Epoetin theta with a new dosing schedule in anaemic cancer patients receiving non-platinum chemotherapy: a randomised control trial. Arch Drug Inf 2010;4:33-41
   Google Scholar
• Hörl WH, Jacobs C, Macdougall IC, European Best Practice Guidelines 17-18: Adverse effects. Nephrol Dial Transplant 2000;15(suppl 4):51-6
   PubMedGoogle Scholar
• Casadevall N, Nataf J, Viron B, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR, Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1385-7
   PubMed Web of Science ®Google Scholar
• Macdougall I, Roger SD, de Francisco A, Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 2012;81:727-32
   PubMed Web of Science ®Google Scholar
• Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int 2008;74:1617-22
   PubMed Web of Science ®Google Scholar
• Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011;80:88-92
   PubMed Web of Science ®Google Scholar
• Port FK, Pisoni RL, Bragg-Gresham JL, DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004;22:175-80
   PubMed Web of Science ®Google Scholar
• For the DOPPS study. Available from: http://www.dopps.org [Last accessed 23 July 2012]
   Google Scholar
• For the ESAM study. European survey on anaemia management. Nephrol Dial Transplant 2000;15(Suppl 4):1-76
   Google Scholar
• Hörl WH, Macdougall IC, Rossert J, Predialysis survey on anemia management: patient referral. Am J Kidn Dis 2003;41:49-61
   PubMed Web of Science ®Google Scholar
• Valderrábano F, Hörl WH, Macdougall IC, Pre-dialysis survey on anemia management. Nephrol Dials Transplant 2003;18:89-100
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Canc 2004;40:2293-306
   PubMed Web of Science ®Google Scholar
• Ludwig H, Aapro M, Bokemeyer C, Treatment patterns, outcomes, and response rates in the management of cancer-related anemia in Europe: findings from the Anemia Cancer Treatment (A.C.T.) study. Eur J Canc 2009;45:1603-15
   PubMed Web of Science ®Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, Modeling of outcomes and response rates to treatment with erythropoiesis stimulating agents in cancer patients with anemia: findings from the Anemia Cancer Treatment (A.C.T.) study. Ann Oncol 2009;20:1714-21
   PubMed Web of Science ®Google Scholar
• Rosencher N, Kerkkamp H, Macheras G, Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: Blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003;43:59-69
   Google Scholar
• Vincent JL, Baron JF, Reinhart K, Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-507
   PubMed Web of Science ®Google Scholar